Moral imperative for immediate release of 2019-nCoV sequence data.
作者信息
Wu Chung-I, Poo Mu-Ming
机构信息
Section Editor for Life Sciences, NSR.
Executive Editor-in-Chief, NSR.
出版信息
Natl Sci Rev. 2020 Apr;7(4):719-720. doi: 10.1093/nsr/nwaa030. Epub 2020 Feb 18.
Abstract
摘要
相似文献
1
Moral imperative for immediate release of 2019-nCoV sequence data.
Natl Sci Rev. 2020 Apr;7(4):719-720. doi: 10.1093/nsr/nwaa030. Epub 2020 Feb 18.
2
Gender differences in moral judgment and the evaluation of gender-specified moral agents.
Cogn Process. 2017 Nov;18(4):399-405. doi: 10.1007/s10339-017-0822-9. Epub 2017 Jun 9.
3
Candidate Targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence Homology- and Bioinformatic-Based Predictions.
SSRN. 2020 Feb 25:3541361. doi: 10.2139/ssrn.3541361.
4
Analysis of the causes of moral injury in the outbreak of 2019-nCoV.
Psychol Trauma. 2020 Aug;12(S1):S162-S164. doi: 10.1037/tra0000720. Epub 2020 Jun 4.
5
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV.
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019. doi: 10.26355/eurrev_202002_20379.
6
2019-nCoV: The Identify-Isolate-Inform (3I) Tool Applied to a Novel Emerging Coronavirus.
West J Emerg Med. 2020 Jan 31;21(2):184-190. doi: 10.5811/westjem.2020.1.46760.
7
Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).
Virusdisease. 2020 Mar;31(1):13-21. doi: 10.1007/s13337-020-00571-5. Epub 2020 Mar 5.
8
Machine intelligence design of 2019-nCoV drugs.
bioRxiv. 2020 Feb 4:2020.01.30.927889. doi: 10.1101/2020.01.30.927889.
9
Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - approach.
J Biomol Struct Dyn. 2021 Aug;39(13):4701-4714. doi: 10.1080/07391102.2020.1781694. Epub 2020 Jun 22.
10
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Allergy. 2022 Aug;77(8):2381-2392. doi: 10.1111/all.15247. Epub 2022 Feb 16.
引用本文的文献
1
On the origin and continuing evolution of SARS-CoV-2.
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
2
A proposal for clinical trials of COVID-19 treatment using homo-harringtonine.
Natl Sci Rev. 2020 Oct 12;8(1):nwaa257. doi: 10.1093/nsr/nwaa257. eCollection 2021 Jan.
3
On the founder effect in COVID-19 outbreaks: how many infected travelers may have started them all?
Natl Sci Rev. 2020 Sep 24;8(1):nwaa246. doi: 10.1093/nsr/nwaa246. eCollection 2021 Jan.
4
A theoretical exploration of the origin and early evolution of a pandemic.
Sci Bull (Beijing). 2021 May 30;66(10):1022-1029. doi: 10.1016/j.scib.2020.12.020. Epub 2020 Dec 16.
5
SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations.
Int J Biol Sci. 2021 Jan 1;17(1):97-106. doi: 10.7150/ijbs.47827. eCollection 2021.
6
The origin and underlying driving forces of the SARS-CoV-2 outbreak.
J Biomed Sci. 2020 Jun 7;27(1):73. doi: 10.1186/s12929-020-00665-8.
本文引用的文献
1
Very fast evolution, not-so-fast publication-a proposed solution.
Natl Sci Rev. 2020 Feb;7(2):237-238. doi: 10.1093/nsr/nwaa010. Epub 2020 Jan 29.
Zotero 插件